Literature DB >> 7595706

Factors that influence collection and engraftment of autologous peripheral-blood stem cells.

W Bensinger1, F Appelbaum, S Rowley, R Storb, J Sanders, K Lilleby, T Gooley, T Demirer, K Schiffman, C Weaver.   

Abstract

PURPOSE: To analyze factors that affect the collection of peripheral-blood stem cells (PBSC) before transplant and the tempo of engraftment after transplant. PATIENTS AND METHODS: A consecutive series of 243 patients with breast cancer (n = 87), malignant lymphoma (n = 90), multiple myeloma (n = 32), or other malignancies (n = 34) had PBSC collected following stimulation with colony-stimulating factors (CSFs) or after chemotherapy followed by CSF. Infusion of PBSC was performed following myeloablative chemotherapy with chemotherapy with or without total-body irradiation (TBI). Postinfusion CSFs were administered to 72 patients. An analysis of factors that influence CD34+ cell yield was performed by linear regression. Cox regression analysis was used to determine factors that affect the kinetics of granulocyte and platelet recovery following infusion of PBSC.
RESULTS: Mobilization with chemotherapy followed by CSF, a diagnosis of breast cancer, absence of marrow disease, no prior history of radiation therapy, and fewer cycles of conventional-dose chemotherapy were associated with a higher average daily yield of CD34+ cells. In the multivariate analysis, the CD34 content of infused cells and the use of a posttransplant CSF influenced neutrophil recovery after infusion of PBSC. CD34 content was also important for predicting platelet recovery. The use of postinfusion CSF was associated with a significant delay in platelet recovery in patients who received less than 5.0 x 10(6) CD34+ cells/kg, but there was no discernable effect in patients who received greater than 5.0 x 10(6) CD34+ cells/kg.
CONCLUSION: Disease status and prior treatment influence the ability to mobilize PBSC. CD34 cell dose is an important predictor of engraftment kinetics after PBSC transplant, regardless of disease or mobilization technique. The use of postinfusion CSF improves neutrophil recovery, but at low CD34 doses can delay platelet recovery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595706     DOI: 10.1200/JCO.1995.13.10.2547

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  55 in total

1.  The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.

Authors:  Antonio Curti; Roberto M Lemoli; Giulia Tolomelli; Katia Mancuso; Paola Tacchetti; Francesca Patriarca; Monica Galli; Lucia Pantani; Beatrice Zannetti; Maria Rosa Motta; Simonetta Rizzi; Elisa Dan; Barbara Sinigaglia; Valeria Giudice; Andrea Olmo; Mario Arpinati; Gabriella Chirumbolo; Renato Fanin; Russell E Lewis; Laura Paris; Francesca Bonifazi; Michele Cavo
Journal:  Bone Marrow Transplant       Date:  2019-11-25       Impact factor: 5.483

2.  Plerixafor.

Authors:  John F DiPersio; Geoffrey L Uy; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

3.  Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission.

Authors:  Jeeyun Lee; Mark H Lee; Keon Woo Park; Jung Hoon Kang; Do Hyung Im; Kihyun Kim; Se-Hoon Lee; Won Seog Kim; Jinny Park; Chul Won Jung; Keunchil Parka
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

4.  Migration against the direction of flow is LFA-1-dependent in human hematopoietic stem and progenitor cells.

Authors:  Alexander Buffone; Nicholas R Anderson; Daniel A Hammer
Journal:  J Cell Sci       Date:  2018-01-10       Impact factor: 5.285

5.  Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.

Authors:  Andreas Humpe; Ute Buwitt-Beckmann; Natalie Schub; Martin Gramatzki; Andreas Günther
Journal:  Transfus Med Hemother       Date:  2013-07-25       Impact factor: 3.747

6.  Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent.

Authors:  Liuyan Jiang; Sunny Malik; Mark Litzow; Dennis Gastineau; Ivana Micallef; Vivek Roy; Lawrence Solberg; Abba C Zubair
Journal:  Transfusion       Date:  2011-08-09       Impact factor: 3.157

Review 7.  Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.

Authors:  M G Kim; N Han; E-K Lee; T Kim
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

8.  Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission.

Authors:  J de la Rubia; G Martín; J Martínez; I Lorenzo; G Sanz; I Jarque; F Moscardó; C Jiménez; P Lorente; A Camps; M A Sanz
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

9.  CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1.

Authors:  Kent W Christopherson; Robin R Frank; Sucheta Jagan; Laura A Paganessi; Stephanie A Gregory; Henry C Fung
Journal:  Exp Hematol       Date:  2012-07-27       Impact factor: 3.084

Review 10.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.